Welcome to our dedicated page for QuidelOrtho news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on QuidelOrtho stock.
QuidelOrtho Corporation reports developments in in vitro diagnostics, including rapid testing, immunoassay and molecular testing, clinical chemistry, transfusion medicine and point-of-care diagnostic platforms. Company updates commonly address financial results, revenue trends, guidance, respiratory testing seasonality, international market conditions and portfolio activity across labs, cardiac, immunohematology and molecular diagnostics.
Recurring news also covers product and technology developments such as the LEX VELO System, a point-of-care molecular PCR platform with FDA 510(k) clearance and CLIA waived status for Flu A, Flu B and COVID-19 testing, as well as diagnostic education topics including syphilis screening and high-sensitivity troponin. Governance and management changes appear alongside business updates and investor conference participation.
QuidelOrtho (Nasdaq: QDEL) released episode 57 of its Science Bytes podcast on April 23, 2026, examining U.S. syphilis trends and rising congenital syphilis.
Key facts: provisional data show a second consecutive year decline in early-stage syphilis, while congenital syphilis reached nearly 4,000 cases in 2024. The episode highlights missed or late prenatal screening and recommends repeat prenatal testing, EHR prompts, and broader screening opportunities to close gaps.
TTP Group announced the sale of spin-out LEX Diagnostics to QuidelOrtho (Nasdaq: QDEL). LEX, founded 2020 from TTP innovation, developed the VELO point-of-care PCR platform.
In February 2026, VELO received FDA 510(k) clearance and CLIA waived status; positives available in as little as 6 minutes, negatives under 10 minutes.
QuidelOrtho (Nasdaq: QDEL) completed the acquisition of LEX Diagnostics for approximately $100 million on April 20, 2026, adding the FDA 510(k)-cleared and CLIA-waived LEX VELO System. The cartridge-based ultra-fast PCR platform delivers multiplex Influenza A/B and COVID-19 results in about six to ten minutes and is slated for a U.S. commercial launch later in 2026, with global expansion subject to local approvals. The deal expands QuidelOrtho's point-of-care molecular diagnostics portfolio and complements its immunoassay, clinical chemistry and transfusion medicine offerings.
QuidelOrtho (Nasdaq: QDEL) reported preliminary unaudited Q1 2026 revenue of $615–$620 million for the quarter ended March 29, 2026, citing a weaker respiratory season and distributor disruptions in China and EMEA. The company expects Q1 free cash flow of $(65)–$(70) million but still expects full-year 2026 free cash flow to be positive. Full Q1 results will be released May 5, 2026, after market close, with a conference call at 2:00 p.m. PT.
QuidelOrtho (Nasdaq: QDEL) appointed Nathaniel "Nate" Sisitsky as Chief Legal Officer, effective March 23, 2026. He will report to CEO Brian Blaser and lead global legal, compliance and corporate governance functions.
Mr. Sisitsky has 25+ years of legal experience across life sciences and technology, most recently serving as Chief Legal Officer and Corporate Secretary at STAAR Surgical. Michelle Hodges is retiring and will advise during the transition.
QuidelOrtho (Nasdaq: QDEL) released episode 56 of its Science Bytes podcast on Feb 19, 2026, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care.
The episode explains how high‑sensitivity troponin (hs troponin) enables earlier detection of cardiac injury, tighter reproducibility at low levels, shorter serial testing protocols (0/1 or 0/2 hour), sex‑specific cutoffs, and emerging applications in cardio‑oncology, perioperative care, and long‑term risk prediction.
QuidelOrtho (Nasdaq: QDEL) said members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference on Tuesday, March 3, 2026 at 1:40 p.m. ET / 10:40 a.m. PT.
According to the company, a live webcast and replay will be available in the Events & Presentations section of its Investor Relations website.
QuidelOrtho (Nasdaq: QDEL) reported fourth-quarter and full-year 2025 results: FY25 revenue $2.73B, adjusted EBITDA $597M with a 22% margin (up 240 bps), and adjusted diluted EPS $2.12. GAAP results included a $701M goodwill impairment, producing a FY25 GAAP net loss of $1.13B and GAAP diluted loss per share of $16.69. The company provided FY26 guidance of $2.7–$2.9B revenue, adjusted EBITDA $630–$670M, adjusted diluted EPS $2.00–$2.42, and free cash flow of $120–$160M. CFO Joseph Busky will retire effective June 30, 2026.
QuidelOrtho (Nasdaq: QDEL) received the Excellence Services Label in EMEA for Customer and Technical Services evaluated to ISO 23592 and is the first medical device company to earn that distinction. QuidelOrtho also won a Gold Stevie for Customer Service Success and a Bronze Stevie for AI & Tech Focused Digital Transformation Team.
The ISO 23592 scope covers Customer Service, Technical Solutions, Technical Training and Field Service; the label affirms maturity and consistent customer focus, while Stevie recognition highlights customer‑experience and digital transformation efforts.
QuidelOrtho (Nasdaq: QDEL) released episode 55 of its Science Bytes podcast on Jan 22, 2026, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. Mullens discusses pressures on the blood supply from routine trauma and climate-driven emergencies, rising demand for O-type units due to low-titer whole blood programs, the role of automation in immunohematology, and the importance of year-round donor engagement. The episode highlights the link between donors, diagnostics, and patient care and is available on major streaming platforms and the company's website.